Manufacturing, Fill/Finish

Catalent Invests Millions to Create European Clinical Manufacturing Center of Excellence

July 21, 2020

Catalent has unveiled investment plans to create a European center of excellence for clinical biologics formulation development and drug product fill/finish services.

R+D Custom Automation Supplies Vial Machinery to SiO2 Materials Science

July 09, 2020

The agreement will accelerate production of SiO2’s plastic vials for vaccines and therapeutics for Operation Warp Speed.

Robotic Inspection System Improves Accuracy

July 09, 2020

Stevanato Group’s Vision Robot Unit uses AI-based machine learning capabilities for particle and cosmetic inspection of biopharmaceutical drug products.

Vetter Expands Fill/Finish Capacity with Acquisition of New Site in Austria

July 08, 2020

The acquisition will give the CDMO additional clinical filling options in Europe, which is expected to come online in 2021.

Grand River Aseptic Manufacturing Opens Large-Scale Injectable Fill/Finish Facility

July 02, 2020

The new facility in Grand Rapids, MI, is part of the CDMO’s aggressive expansion plan.

Inovio to Scale-Up Manufacture of Intradermal Delivery Device for its COVID-19 Vaccine

June 24, 2020

Inovio received a $71-million contract from the US Department of Defense to scale up manufacture of its Cellectra smart device to deliver its DNA vaccine.

Corning Expands Glass Vial Capacity

June 17, 2020

Corning will use BARDA funding to expand US manufacturing capacity for pharmaceutical tubing and vials made from Valor glass.

SiO2 Scales Up Container Technology for COVID-19 Vaccines and Treatments

June 08, 2020

SiO2 Materials Science has received $143 million from the US government to accelerate capacity scale-up of its advanced primary packaging platform.

Ajinomoto Bio-Pharma Services, Humanigen in Manufacturing Agreement for COVID-19 Biologic

June 01, 2020

The companies have entered into a manufacturing agreement for the fill finish supply of lenzilumab for the potential treatment of COVID-19.

Risk Aversion Remains an Obstacle to Innovation in Closed Systems

May 12, 2020

Risk aversion is impeding the use of closed aseptic systems, and adding unnecessary cost and complexity to aseptic operations in the pharma industry.